- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04297436
Gonococcal Vaccine Study in Key Populations in Kenya (BexKPK)
Use of Bexsero Immunisation to Detect Cross Reactive Antigens and Anti-gonococcal Antibodies in Key Populations in Kenya
Gonorrhoea is a sexually transmitted infection that can infect both men and women. It can cause infections in the genitals, rectum, and throat. It is a very common infection, especially among young people aged 18-25 years.
Meningococcal disease and gonorrhoea are caused by bacteria that are closely related but cause different diseases that are spread in different ways. New evidence suggests that the Meningococcal B vaccine (Bexsero®) licensed outside of Kenya against meningococcal B disease may also be effective against gonorrhoea due to genetic similarities between the two organisms causing the two diseases. The aim of this study is to generate data to develop a gonorrhoea vaccine, using an existing vaccine against meningococcal disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Kilifi, Kenya
- KEMRI-Wellcome Trust Research Programme
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male and female as assessed by a medical history, physical exam, and laboratory tests (specified in study operations manual).
- At least 18 years of age on the day of screening and will not reach 26th birthday on the day of the second vaccination (approximately 6 weeks after enrolment)
- Willing and able to give informed consent for participation in the trial before any study-related procedures are performed.
- Willing to donate blood samples for immunogenicity assessments.
Exclusion Criteria:
Any clinically significant acute or chronic medical condition that is considered progressive that, in the opinion of the Principal Investigator or designee, makes the volunteer unsuitable for participation in the trial
- Pregnancy
- Participation in another clinical trial (i.e. investigational HIV vaccine candidate), within the previous 3 months or expected participation during the study
- Bleeding disorder diagnosed by a physician (e.g., factor deficiency, coagulopathy or platelet disorder that requires special precautions).
- History of severe local or systemic reactogenicity to vaccines (e.g., anaphylaxis, respiratory difficulty, angioedema).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Bexsero
Each participant is compared to baseline (before vaccination)
|
Tthe 4CMenB vaccine (Bexsero®) contains the MeNZB OMV component plus three recombinant antigens (NadA, fHBP-GNA2091, and NHBA-GNA1030.
The 4CMenB vaccine (Bexsero®) induces antibodies in humans that recognise gonococcal proteins.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
humoral and T cell cross-reactive responses against Neisseria gonorrhoeae
Time Frame: approximately 2 weeks following completed vaccination (2 doses)
|
Serum antigen- and OMV-specific IgG1, IgG2a, Ig3A and IgA titres will be determined. T cell responses will be measured in two ways: Indirect responses: by determining the IgG1/IgG2 ratios after immunization. Direct responses: PBMCs will be isolated at enrolment, 2 weeks post second immunization and used for the detection of antigen-specific IFN secreting T cells. The induction of antibody will be measured by a standard endpoint ELISA assay using peptides covering recombinant protein antigens, purified antigens, and defined OMVs. After the final immunization, PBMCs will be collected for isolation of antigen-specific memory B cells, aiming to generate human monoclonal antibodies (mAbs) against key vaccine candidates. |
approximately 2 weeks following completed vaccination (2 doses)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Eduard Sanders, MD, PhD, University of Oxford & KEMRI-Wellcome Trust
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSC 182
- OXTREC16-20 (Other Identifier: University of Oxford)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
All trial data will be entered in the clinical trial database, which are maintained through Standard Operating Procedures.
The volunteer will be identified by a unique trial specific number and/or code in any database. The name and any other identifying detail will NOT be included in any trial data electronic file.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gonorrhea
-
Melinta Therapeutics, Inc.National Institute of Allergy and Infectious Diseases (NIAID)CompletedUncomplicated Urogenital GonorrheaUnited States, Australia
-
Melinta Therapeutics, Inc.CompletedUncomplicated Urogenital GonorrheaUnited States
-
University of WashingtonCompleted
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)RecruitingGonorrhea MaleUnited States
-
University of North Carolina, Chapel HillLondon School of Hygiene and Tropical Medicine; National Institute of Allergy... and other collaboratorsCompleted
-
University of California, Los AngelesEmory University; University of California, San Francisco; Asociacion Civil Via...Active, not recruitingChlamydia | HIV-1-infection | Partner Communication | Gonorrhea MalePeru
-
University of California, Los AngelesRecruitingMethamphetamine-dependence | Rectal Gonorrhea | Rectal ChlamydiaUnited States
-
University of Maryland, BaltimoreTerminatedSexually Transmitted Infection | Gonorrhea Female | Chlamydia FemalesUnited States
-
Population CouncilBill and Melinda Gates Foundation; Centers for Disease Control and Prevention; Ministry of Health, Thailand and other collaboratorsCompletedHIV Infections | Syphilis | Trichomonas Vaginitis | Chlamydia Trachomatis | Nesseria GonorrheaThailand
-
Global Antibiotics Research and Development PartnershipActive, not recruitingGonorrheaUnited States, Belgium, South Africa, Netherlands, Thailand
Clinical Trials on 4CMenB (Bexsero®) vaccine
-
University of AdelaideSA HealthCompletedMeningococcal DiseaseAustralia
-
Kirby InstituteGriffith UniversityActive, not recruitingNeisseria Gonorrheae InfectionAustralia
-
Ospedale Policlinico San MartinoGlaxoSmithKlineCompletedAcquired ImmunodeficiencyItaly
-
Chinese University of Hong KongRecruitingGonorrhea | Sexually Transmitted InfectionHong Kong
-
University of OxfordImperial College London; Public Health England; Novartis Vaccines; European CommissionCompleted
-
St George's, University of LondonGlaxoSmithKline; Public Health England; MeningitisNowCompletedPrematurity | Meningococcal Disease | VaccinationUnited Kingdom
-
University of OxfordCompletedMeningococcal Infections | Neisseria Meningitidis | Meningococcal Vaccines | Factor H-binding Protein, Neisseria MeningitidiUnited Kingdom
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences InstituteCompletedNeisseria Gonorrhoeae InfectionUnited States
-
Novartis VaccinesGlaxoSmithKlineCompletedMeningococcal Meningitis | Meningoccocal DiseaseHungary, Spain
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningococcal Immunisation (Healthy Volunteers)United States, Puerto Rico